News and Events

News

All categories

Earnings

Press Release

All years

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

October 29, 2021

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

October 1, 2021

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

September 8, 2021

Affimed to Present at Upcoming Investor Conferences

August 26, 2021

Affimed to Present at Upcoming Investor Conferences

August 26, 2021

Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021

August 23, 2021

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

July 30, 2021

Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress

July 1, 2021

Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021

June 22, 2021

Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

June 16, 2021

Events

All

Scientific

Investors

There are no events planned at the moment.

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

Affimed to Present at Upcoming Investor Conferences

Affimed to Present at Upcoming Investor Conferences

Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress

Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021

Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

Events